G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because, once again, that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, though, yes? To cope, of course, we are quaffing cups of stimulation — we are indulging our taste for Southern Pecan, for those keeping track — and invite you to join us. Meanwhile, here are some tidbits. Hope you have a smashing day and do keep in touch. We appreciate your ideas, thoughts, and tips …

Drug makers spent $5.6 billion on direct-to-consumer ads last year, a 9 percent increase, according to Medical Marketing & Media, citing data from Nielsen. And once again, Pfizer and Bristol-Myers Squibb took the two top spots among drug makers, spending $1.1 billion and $458 million, respectively. AbbVie, Eli Lilly, and Allergan rounded out the top five spenders. Bristol-Myers Squibb spent more than $170 million on the Opdivo cancer drug alone.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.